Holding(s) in Company (0398I)
08 Juin 2011 - 8:00AM
UK Regulatory
TIDMMDST
RNS Number : 0398I
Medicsight Plc
08 June 2011
Press Release 8 June 2011
Medicsight PLC
("Medicsight" or "the Company")
Notifiable Interest
The Company received the following notification on 7 June
2011:
TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES
------------------------------------------------
1. Identity of the issuer or the underlying
issuer
of existing shares to which voting rights
are
attached: Medicsight PLC
------------------------------------------------ ----------------------------
2. Reason for the notification (please tick the appropriate box
or boxes):
------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
-------------------------------------------------------------------- --------
An acquisition or disposal of qualifying financial instruments
which may result in the acquisition of shares already
issued to which voting rights are attached
-------------------------------------------------------------------- --------
An acquisition or disposal of instruments with similar
economic effect to qualifying financial instruments
-------------------------------------------------------------------- --------
An event changing the breakdown of voting rights
-------------------------------------------------------------------- --------
Other (please specify):
-------------------------------------------------------------------- --------
3. Full name of person(s) subject
to the
notification obligation: MGT Capital Investments, Inc.
--------------------------------------- -------------------------------------
4. Full name of shareholder(s)
(if different from 3.):
--------------------------------------- -------------------------------------
5. Date of the transaction and
date on
which the threshold is crossed
or
reached: 6 June 2011
--------------------------------------- -------------------------------------
6. Date on which issuer notified: 7 June 2011
--------------------------------------- -------------------------------------
7. Threshold(s) that is/are crossed
or
reached: 55% to 53%
--------------------------------------- -------------------------------------
8. Notified details:
-----------------------------------------------------------------------------------------------
A: Voting rights attached to shares
------------------------------------------------------------------------------------------------
Class/type
of shares
if possible Situation previous
using the to the triggering Resulting situation after the triggering
ISIN CODE transaction transaction
--------------- ------------------------ -----------------------------------------------------
Number of Number
Number of Voting of Number of voting % of voting
Shares Rights shares rights rights
-------------- ---------- ------------ ----------
Direct Direct Indirect Direct Indirect
-------------- ---------- ------------ ---------- ---------- --------- ------- ---------
ordinary 86,000,000 86,000,000 83,910,000 83,910,000 53.94%
--------------- ---------- ------------ ---------- ---------- --------- ------- ---------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of
financial date Conversion rights that may be voting
instrument Period acquired if the rights
instrument is
exercised/converted
----------- ------------------------ ------------ --------------------- ------------
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments
---------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of % of voting
financial price date Conversion voting rights
instrument period rights
instrument
refers to
----------- ---------------------- ------------ ------------ ------------ --------------
Nominal Delta
----------- ---------------------- ------------ ------------ ------------ ------- -----
Total (A+B+C)
------------------------------------------------------------------
Number of voting rights % of voting rights
------------------------------------ ----------------------------
83,910,000 53.94%
------------------------------------ ----------------------------
9. Chain of controlled undertakings through which the voting
rights and/or the financial instruments are effectively held,
if applicable:
------------------------------------------------------------------
Proxy Voting:
------------------------------------------
10. Name of the proxy holder:
------------------------------------------
11. Number of voting rights proxy
holder
will cease to hold:
------------------------------------------
12. Date on which proxy holder
will cease to
hold voting rights:
------------------------------------------
13. Additional information:
--------------------------------------- -----------------
14. Contact name: Robert Ladd
--------------------------------------- -----------------
15. Contact telephone number: +1-212-652-3214
--------------------------------------- -----------------
- ENDS -
For further information:
Medicsight plc
Allan Rowley, CEO Tel: +44 (0)207 605 7950
www.medicsight.com
follow us on twitter
@Medicsight
Daniel Stewart & Co
Noelle Greenaway / Oliver Rigby Tel: +44 (0) 207 776 6550
www.danielstewart.co.uk
Media enquiries:
Abchurch
www.abchurch-group.com
Julian Bosdet Tel: +44 (0) 207 398 7700
julian.bosdet@abchurch-group.com
Adam Michael Tel: +44 (0) 207 398 7708
adam.micheal@abchurch-group.com
Simone Elviss Tel: +44 (0) 207 398 7728
simone.elviss@abchurch-group.com
Quincy Allan Tel: +44 (0) 207 398 7710
quincy.allan@abchurch-group.com
Notes to editors
Medicsight plc is a UK-headquartered, research driven, leading
developer of computer-aided detection (CAD) and image analysis
software for the medical imaging market. The CAD software
automatically highlights suspicious areas on computerised
tomography (CT) scans of the colon, helping radiologists to
identify, measure and analyse potential disease and early
indicators of disease. Medicsight's CAD software has been developed
using a large and population diverse database of verified patient
CT scan data. Medicsight's ColonCAD(TM) software products are
seamlessly integrated with the advanced 3D visualisation
workstations of several industry-leading imaging equipment
partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware
such as Multi-Detector CT scanners, radiologists are facing a
growing challenge in the amount of detailed patient image data that
they must review for each patient examination. Some CT scan
examinations generate as many as 2000 images per patient. Review of
this data by the radiologist is not only time-consuming but also
prone to error due to reader fatigue. CAD software can help the
reviewing radiologist by analysing the image data and automatically
highlighting suspicious regions of interest for closer inspection.
Without CAD software some potential abnormalities or areas of
disease may be overlooked. This can be critical for diagnosis and
the management of patient outcomes as early detection of disease
greatly increases the probability of successful treatment and a
positive therapeutic outcome. In addition to supporting individual
radiologists CAD also has the potential to help standardise CT
interpretation across both individuals and institutions thereby
supporting population based screening programmes.
About Medicsight's CAD software
Medicsight's ColonCAD(TM) software uses an advanced CAD
algorithm to analyse CT scans of the colon and automatically
highlight suspicious areas that may be indicators of disease. CAD
may highlight areas easily overlooked by the reviewing radiologist,
such as small lesions or regions that are hidden from view behind
folds in the colon.
ColonCAD can be seamlessly integrated with advanced 3D
visualisation platforms of industry-leading imaging equipment
partners. The integrated systems provide sophisticated image
viewing capabilities, including 3D reconstructed image data, with
the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of
disease.
Since inception, Medicsight has developed close and lasting
relationships with some of the world's foremost clinicians in
product related areas. This provides the Company with a wealth of
clinical expertise and dedicated clinical research to support
ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research
programmes worldwide to develop the Company's comprehensive
database of population diverse verified patient CT scan data, thus
allowing Medicsight's products to be validated to the highest
possible standards.
About colorectal cancer
According to the American Cancer Society, colorectal cancer is
one of the leading causes of cancer-related deaths in the United
States with an estimated 49,000 colorectal cancer deaths expected
during 2011. However regular screening (where polyps can be
detected at an early stage before they have developed into cancer)
is one of the most powerful methods of colorectal cancer
prevention. Screening for colorectal polyps increases the
probability of more colorectal cancers being detected earlier -
when the disease is easier to cure.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLKDLFBFQFLBBQ
Medicsight (LSE:MDST)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Medicsight (LSE:MDST)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
